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Abstract
Purpose: Retinal dystrophies are genetically heterogeneous, resulting from mutations in over 200 genes. Prior to the
development of massively parallel sequencing, comprehensive genetic screening was unobtainable for most patients.
Identifying the causative genetic mutation facilitates genetic counselling, carrier testing and prenatal/pre-implantation
diagnosis, and often leads to a clearer prognosis. In addition, in a proportion of cases, when the mutation is known
treatment can be optimised and patients are eligible for enrolment into clinical trials for gene-specific therapies.
Methods: Patient genomic DNA was sheared, tagged and pooled in batches of four samples, prior to targeted capture and
next generation sequencing. The enrichment reagent was designed against genes listed on the RetNet database (July 2010).
Sequence data were aligned to the human genome and variants were filtered to identify potential pathogenic mutations.
These were confirmed by Sanger sequencing.
Results: Molecular analysis of 20 DNAs from retinal dystrophy patients identified likely pathogenic mutations in 12 cases,
many of them known and/or confirmed by segregation. These included previously described mutations in ABCA4 (c.6088C.
T,p.R2030*; c.5882G.A,p.G1961E), BBS2 (c.1895G.C,p.R632P), GUCY2D (c.2512C.T,p.R838C), PROM1 (c.1117C.T,p.R373C),
RDH12 (c.601T.C,p.C201R; c.506G.A,p.R169Q), RPGRIP1 (c.3565C.T,p.R1189*) and SPATA7 (c.253C.T,p.R85*) and new
mutations in ABCA4 (c.3328+1G.C), CRB1 (c.2832_2842+23del), RP2 (c.884-1G.T) and USH2A (c.12874A.G,p.N4292D).
Conclusions: Tagging and pooling DNA prior to targeted capture of known retinal dystrophy genes identified mutations in
60% of cases. This relatively high success rate may reflect enrichment for consanguineous cases in the local Yorkshire
population, and the use of multiplex families. Nevertheless this is a promising high throughput approach to retinal
dystrophy diagnostics.
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Introduction
Retinal dystrophies are to date the most genetically heteroge-
neous set of inherited conditions known to affect a single organ.
This complicates genetic screening for conditions such as retinitis
pigmentosa (RP), cone-rod dystrophy (CRD) and Leber congenital
Amaurosis (LCA) since each can result from mutations in many
genes (see RetNet, https://sph.uth.tmc.edu/retnet/) which, with
the exception of LCA, follow dominant, recessive or X-linked
patterns of inheritance. Nationally, inherited retinal disease
accounts for 4.2% of all sight impairment certifications and
5.5% of blindness cases [1]. These diseases are a more significant
issue in the West Yorkshire population due to the high incidence of
first cousin marriage and consequent recessive disease in the local
Pakistani community [2]. Until recently, patients could at best be
offered only limited counselling based on approximate recurrence
rates for a given mode of inheritance, whilst presymptomatic
diagnosis and carrier status testing were impossible in all but a
minority of cases. A further incentive for seeking to improve this
situation is the notable success of an increasing number of clinical
trials for gene and other targeted therapies for retinal dystrophies
[3–7]. These are gene-specific, meaning that only patients for
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whom mutations have been identified will benefit from these novel
approaches to stratified medicine.
In order to increase patient recruitment to new gene- or
mutation-specific trials, several groups have already highlighted
the potential of next generation sequencing in disease diagnosis
[8–14]. Here we confirm the efficacy of this approach in a
Northern UK cohort. In addition we describe the use of a
previously published approach, tagging and DNA pooling prior to
targeted capture and next generation sequencing [15], providing a
valuable refinement to existing high throughput next generation
sequencing strategies for identifying the genetic basis of retinal
dystrophy.
Materials and Methods
Ethics Statement
Patients and their relatives recruited to the study gave informed,
written consent using a process approved by the Leeds East
Research Ethics committee (Project number 03/362), adhering to
the tenets of the Declaration of Helsinki.
Samples
The families were selected on the basis that there were multiple
affected members with an unidentified molecular genetic diagno-
sis. The patients were diagnosed with a retinal dystrophy by an
experienced ophthalmologist. Pedigree structures are depicted in
Figure 1, while diagnoses, possible inheritance patterns, ethnicity
and summary information regarding numbers of affected cases
and members who were available for sampling are recorded in
Table S1 in File S1. Peripheral blood was collected from affected
patients, their parents and unaffected relatives where available.
Genomic DNA was extracted from blood according to standard
procedures.
Target design
In order to enrich specific regions of the patient’s genomic
DNA, a liquid-phase reagent comprising ‘SureSelect Target
Enrichment’ biotinylated cRNA baits was designed using the
Agilent Technologies eArray software (http://www.genomics.
agilent.com/) (Agilent Technologies UK Limited, Wokingham,
UK). In total, 2,988 coding exons as well as a single intronic
region, and their 100 bp flanking sequences, were selected in the
UCSC genome database (http://www.genome.ucsc.edu/) from all
Figure 1. Family pedigrees of patients that were studied. Individuals from whom DNA was available are assigned the DNA notation in small
lettering to the top right hand side of the symbol (and are also numbered). * highlights pedigrees that have been abbreviated for this figure.
doi:10.1371/journal.pone.0104281.g001
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of the 162 genes implicated in retinal degeneration (RetNet, July
2010). The list of genes targeted is shown in Table S2 in File S1.
This consisted of 46,287 RNA baits at 56 tiling to cover 776.5 kb
of DNA sequence. Probes could not be designed against 9 exons
(Table S3 in File S1).
Library construction and massively parallel sequencing
Genomic DNA was sheared using a Covaris S220 sonicator.
Illumina sequencing adapters containing 6 bp sequence tags were
ligated to the samples, with each DNA sample being ligated to a
different tag. The tagged DNA libraries were pooled into batches
and captured using the SureSelect custom baits according to the
manufacturer’s instructions. Each captured pool was sequenced
using single-end 80 bp reads on an Illumina GAIIx Sequencer
(Illumina Inc., Little Chesterford, UK) according to the manufac-
turer’s instructions.
Alignments and variant detection
Sequence data were generated in qseq format and barcode
sorted by their unique 59 tag using NovoSort. The sorted fastq files
have been deposited in the European Nucleotide Archive (http://
www.ebi.ac.uk/ena/) with study accession number, PRJEB6380.
The reads were aligned to the human genome sequence, hg19,
using Novoalign (v2.08.01). Following realignment around indels,
the GATK (v2.0.34) Unified Genotyper was used to identify
variants [16]. The output VCF files were annotated for analysis
using Alamut-HT (v1.0.4) (Interactive Biosoftware, Rouen,
France). Analysis of read depth was performed using BEDTools
(v2.15.0) and the GATK Count Reads walker.
Variants were filtered to exclude those more than 5 bp beyond
the splice site junction. Synonymous variants and those with minor
allele frequencies $0.01 in dbSNP or the 1,000 genomes project
were also excluded.
From the remaining list, variants were then selected for further
analysis if they met one or both of the following criteria. Firstly,
variants that occurred in genes that had previously been associated
with the observed phenotype and showed the expected pattern of
inheritance were selected. Secondly, null alleles resulting from
nucleotide deletions or insertions, premature stop codon mutations
or changes affecting the conserved 2 bp adjacent to the splice site
junction as well as missense variants with at least 2 out of 4 high
pathogenicity scores were selected. For a high pathogenicity
profile, scores recorded in the Alamut-HT report included
BLOSUM62 (Blocks Substitution Matrix; http://www.uky.edu/
Classes/BIO/520/BIO520WWW/blosum62.htm) ,0, AGVGD
(Align Grantham Variation and Grantham Deviation; http://
agvgd.iarc.fr/agvgd_input.php) between C15 and C65, SIFT
(Sorts Intolerant From Tolerant substitutions, http://sift.jcvi.org)
,0.05 or deleterious and MAPP (Multivariate Analysis of
Protein Polymorphism; http://mendel.stanford.edu/SidowLab/
downloads/MAPP) = bad. A schematic for the sequencing and
informatics pipeline is shown in Figure 2. For any cases with a
diagnosis of LCA, the unfiltered variant lists were also analysed for
the deep intronic mutation c.2991+1655A.G in CEP290 that
causes this phenotype [17].
Sanger sequencing of potential disease-causing variants
Variants selected by the above criteria were confirmed by
conventional Sanger sequencing of patient genomic DNA using
the BigDye terminator cycle sequencing kit (Applied Biosystems,
Paisley, UK) on an ABI3130xl sequencer (Applied Biosystems) and
analysed using Sequencing Analysis v.5.2 software (Applied
Biosystems). This was used to confirm presence of the mutation
and test whether the mutation segregated with the disease
phenotype in the family in question.
Confirmed pathogenic mutations were deposited in the publicly
available LOVD database (http://databases.lovd.nl/shared/).
Results
Validating the capture reagent and establishing a
pipeline for variant detection
To test the feasibility of identifying pathogenic mutations in
genomic DNA from patients with retinal degeneration, we selected
four patients in whom, by Sanger sequencing of candidate genes,
we had identified mutation(s) deemed clearly causative based on
exclusion from control cohorts, predicted pathogenicity and
segregation in additional family members. The analysis of the
data for this study was conducted by one of the co-authors (David
A Parry) without prior knowledge of these known mutations in the
samples. Briefly, a sequencing adapter containing a different 6 bp
sequence tag was ligated to each patient’s sonicated DNA. The
tagged aliquots were pooled prior to hybridisation against the
target enrichment reagent and run on a single lane of the Illumina
GAIIx DNA sequencer. The sequence data for each sample was
sorted by sequence tag and aligned against the human reference
sequence for analysis of coverage and read depth (Table 1).
Pooling of 4 samples gave a range of coverage between 95.6% to
96.9% with at least 20 good quality reads following duplicate
removal and between 1 and 2% that had less than 56 read depth.
A list of variants was generated for each sample and these were
Figure 2. Schematic for next generation sequencing and
variant detection. The strategy for NGS library preparation (A) and
informatics used (B) are depicted.
doi:10.1371/journal.pone.0104281.g002
NGS for Retinal Disease Diagnosis
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filtered without family history information according to the criteria
highlighted in Table 2, and described in the Methods section, to
give rise to a list of candidate variants for each sample (Table S4 in
File S1).
Prioritisation of the variants was based on whether the genotype
was consistent with disease symptoms in the family, the variant
type and pathogenicity scores. For sample A with a diagnosis of
RP, heterozygous mutations in RP9, RP1 and FSCN2 were
deemed consistent with disease symptoms, and of these a high
pathogenicity profile suggested that the strongest candidate for
causation in sample A was the RP9 variant. For sample B, though
a number of changes were observed, only compound heterozy-
gosity for a premature stop codon and a high pathogenicity
missense mutation in CRB1 fitted with the LCA diagnosis in this
patient. For sample C, heterozygous variants in RP1 and a
homozygous variant in USH2A were considered possible candi-
dates for causing RP in this patient. However based on
pathogenicity scores and variant type, the strongest candidates
for disease causation in sample C were the RP1 variants. For
sample D, only a null mutation in PRPF31 was identified as
consistent with the diagnosis of RP.
The variants that had previously been deemed causative in each
sample are shown in Table 3. As these variants had indeed been
implicated as candidates for pathogenicity following filtering and
prioritisation as highlighted above, without the need for segrega-
tion analysis, this confirmed that the pipeline used to identify
pathogenic mutations was robust.
Screening patients with unknown mutations
We then selected 20 patients with various retinal degenerations
for which no mutation had yet been identified and performed the
pre-capture pooling procedure on the tagged DNA libraries
pooled in batches of four samples. Following alignment, variant
detection and filtering as described in the Methods, a list of
candidate variants were identified for each sample (Table S5 in
File S1). Candidate variants were prioritised as described
previously and Sanger sequenced to confirm the presence of the
mutation. Segregation was performed where DNA from other
family members was available.
For MA1, family history suggested LCA with recessive
inheritance caused by an autozygous mutation. The variant list
following analysis of patient 2906 (a female) suggested the
homozygous CRB1 mutation (c.2832_2842+23del) as the only
candidate consistent with the diagnosis in the family [18]. Analysis
of the other affected case from whom DNA was available (2907)
confirmed the CRB1 mutation as the pathogenic cause of disease.
For MA2, family history of the index case (2844, a male) with
unaffected parents and consanguinity suggested recessive inheri-
tance caused by an autozygous mutation. The variant list following
analysis of this case suggested a previously-identified homozygous
nonsense mutation in ABCA4 (c.6088C.T, p.R2030*) [19]
consistent with a diagnosis of CRD as the primary candidate.
This mutation was indeed confirmed in the index case and
subsequently found to be heterozygous in his affected offspring
(2843 and 2845) suggesting that they both had an unidentified
ABCA4 mutation on their other allele which they had inherited
from their mother.
For MA3, family history suggested RP with recessive inheri-
tance due to an autozygous mutation. The variant list following
analysis of patient 2908 (a female) identified a homozygous
missense variant in USH2A (c.12874A.G, p.N4292D) with a
high pathogenicity profile as the sole candidate. The USH2A
mutation was indeed subsequently confirmed in both affected
cases from whom DNA was available.
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For MA4, family history suggested recessive inheritance of RP
and an autozygous mutation. The variant list following analysis of
case 2833 (a male) highlighted two homozygous missense variants
in EYS as possible candidates. Following analysis of the other
affected case (2910), both EYS variants were homozygous and
Sanger sequencing of the EYS terminal exon that was not covered
by the capture reagent failed to identify any other changes. One of
the EYS variants (c.7558T.C, p.F2520L) disrupts the second
laminin G subdomain which is essential for normal protein
function [20]. Given the degree of co-segregation and consistency
with phenotype, this was considered the most likely variant to be
pathogenic, but given the low pathogenicity profile scores due to
the lack of amino acid conservation of the normal residue in
vertebrates (data not shown), the variant was considered unproven.
For MA5 family history suggests dominant inheritance of a
CRD phenotype. The variant list following analysis of patient
2278 (a female) did not highlight any obvious candidates.
For MA6, family history suggested recessive inheritance of RP
with an autozygous mutation. The variant list described a
previously identified homozygous missense mutation in RDH12
(c.601T.C, p.C201R) [21] with a high pathogenicity profile
which was confirmed in the case (a male) as the likely cause of
disease.
For MA7, family history suggested dominant inheritance of
CRD. The variant list following analysis of patient 114 (a male)
highlighted the heterozygous PROM1 mutation (c.1117C.T,
p.R373C) which was previously identified in patients with a
diagnosis of cone-rod dystrophy [22,23] as the possible cause of
disease symptoms. This was confirmed by segregation in the
family.
For MA8, family history suggested dominant or X-linked
inheritance of RP with macular involvement. The variant list
derived from analysing case 40 (a male) described a dominant
variant in NR2E3 and an X-linked variant in RP2 as the most
likely candidates. Analysis of the variants in additional family
members for segregation identified that only the splicing variant in
RP2 (c.884-1G.T) followed disease symptoms as X-linked
dominant inheritance in the family.
For MA9, family history suggested dominant inheritance of a
macular dystrophy phenotype. The variant list derived from
analysing case 530 (a female) identified heterozygous variants in
HMCN1 and the previously reported GUCY2D [24,25] as the
most likely candidates. Analysis of additional family members from
whom DNA was available only confirmed segregation of the
GUCY2D mutation (c.2512C.T, p.R838C) with disease symp-
toms in the family.
For MA10, family history suggested recessive inheritance of
CRD with an autozygous mutation. The variant list from
analysing case 1857 (a male) highlighted only one candidate, a
homozygous null variant in RPGRIP1 (c.3565C.T, p.R1189*)
that was recently reported independently as a pathogenic cause of
disease [26]. Segregation analysis confirmed this mutation as the
cause of disease symptoms in this family.
For MA11, family history suggested recessive RP with an
autozygous mutation. The variant list derived from analysing
patient 2093 (a male) described a homozygous missense variant in
BBS2 (c.1895G.C, p.R632P) as the most likely candidate.
Analysis of the other affected case 1267 confirmed that the
BBS2 mutation, which was recently reported to be a common
cause of RP in the Ashkenazi Jewish population [27], was the likely
pathogenic cause of disease.
For MA12, family history suggested recessive CRD. The variant
list derived from case 1024 (a male) highlighted two heterozygous
missense variants in CDH23 as possible candidates even though
recessive mutations in this gene usually cause Usher syndrome.
The absence of segregation in other family members suggested
that these variants were not the pathogenic cause of disease in this
family.
For MA13, family history suggested recessive inheritance of RP.
Analysis of the variant list from case 863 (a female) identified
missense variants in GPR98 and MYO7A as the best candidates
even though mutations in these genes usually cause recessive
Usher syndrome. On the basis of higher pathogenicity profiles, the
GPR98 variants were analysed further. Segregation analysis
confirmed that these variants were not the cause of disease
symptoms in this family.
For MA14, family history suggested RP with recessive
inheritance due to an autozygous mutation in each case. The
variant lists for patient 1518 (a male), identified two heterozygous
variants in BBS12 and one in FSCN2 as possible candidates
though neither option appeared to fit the observed phenotype
perfectly. Following analysis of the other affected sibling (1527)
these variants did not segregate with the disease phenotype and so
were unlikely to be the pathogenic cause of disease in this family.
For MA15, family history suggested recessive CRD with an
autozygous mutation. The variant list for patient 3283 (a male)
identified a previously been reported homozygous null variant in
SPATA7 (c.253C.T, p.R85*) [28] as the most likely candidate.
Analysis of DNA from other family members highlighted that this
variant segregated with the disease phenotype as expected.
For MA16 with a diagnosis of LCA, family history of the index
case (3341, a male) suggested recessive inheritance and an
autozygous mutation. The variant list from analysing 3340
highlighted only the previously reported LCA causing RDH12
variant (c.506G.A, p.R169Q) [29] as the likely cause of disease.
This mutation was confirmed in the other family member.
For MA17, family history suggested recessive inheritance of
RCD caused by an autozygous mutation. From the variant list of
patient 3347 (a male), no obvious candidates could be identified.
For MA18, family history suggested CRD with recessive
inheritance. From analysing the variant list of case 1484 (a
female), compound heterozygous variants in ABCA4 for the
Table 2. Filtering the variant lists following targeted capture and next generation sequencing for the 4 patient verification study.
Filtering process Patient A Patient B Patient C Patient D
Total variants identified 614 564 595 580
Exclude outside exon/splice junction 278 282 269 260
Exclude synonymous variants 134 142 131 124
Exclude if MAF $0.01 7 12 10 3
Exon constitutes coding variants only. Splice junction constitutes +/25 bp around an exon. A full list of variants is shown in Table S4.
doi:10.1371/journal.pone.0104281.t002
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previously reported missense variant (c.5882G.A, p.G1961E)
[30,31] as well as the heterozygous splicing variant (c.3328+1G.
C) suggested these changes as the most likely to account for the
CRD in this family. This was confirmed by segregation analysis of
the variants.
For MA19 family history suggested recessive inheritance of
RCD with recessive inheritance with an autozygous mutation. The
variant list of patient 1885 (a male), identified compound
heterozygous variants in CC2D2A and PCDH15 as well as a
variant in WFS1 with a high pathogenicity profile as possible
candidates though none of the options appeared to fit the observed
phenotype perfectly. Analysis of family members from whom
DNA was available confirmed three of the putative variants were
artefacts and the remaining ones in CC2D2A and WFS1 did not
segregate with disease.
For MA20, family history suggested RP with recessive
inheritance due to an autozygous mutation. The variant list of
case 472 (a male) identified a single homozygous missense variant
in TRPM1 as well as compound heterozygous variants in
CEP290 and a variant in CA4, though none of these candidates
appeared to exactly fit the observed phenotype. As suspected,
these variants were either artefacts or failed to segregate with
disease in this family suggesting that the pathogenic cause of
disease has yet to be identified.
Using this approach likely pathogenic mutation(s) were identi-
fied in 12 out of 20 cases (60%). A list of these mutations is
highlighted in Table 4 and the sequence chromatograms of each
candidate variant highlighted in Figure S1 in File S1. To
summarise, the mutations consisted of previously reported
mutations of clinical significance in ABCA4 (c.6088C.T,
p.R2030* [19] and c.5882G.A, p.G1961E [30,31]), RDH12
(c.601T.C, p.C201R [21] and c.506G.A, p.R169Q [29]),
PROM1 (c.1117C.T, p.R373C [22,23]), GUCY2D (c.2512C.
T, p.R838C [24,25]), RPGRIP1 (c.3565C.T, p.R1189* [26]),
BBS2 (c.1895G.C, p.R632P [27]) and SPATA7 (c.253C.T,
p.R85* [28]) and new mutations in CRB1 (c.2832_2842+23del),
USH2A (c.12874A.G, p.N4292D), RP2 (c.884-1G.T) and
ABCA4 (c.3328+1G.C). Of the 8 cases for which the pathogenic
mutation could not be identified, the absence of zero-coverage
targeted regions suggested that a homozygous deletion removing
an exon(s) was not the cause of disease in these patients.
Discussion
In this paper we describe a previously published strategy for
target capture and next generation sequencing that utilises tagging
and pooling of DNAs in batches of four prior to enrichment [15].
This approach refines the use of targeted capture technology,
facilitating the enrichment of exons from pooled samples using a
single aliquot of capture reagent. This strategy differs from
previously described methods which usually pool samples after the
hybridization step to multiplex onto one lane of the sequencer.
The technology described herein will contribute to the develop-
ment of a retinal dystrophy diagnostic screening service by
reducing costs associated with using a single capture reagent to
analyse up to four samples in a single experiment. We also describe
use of a reagent designed to enrich patient genomic DNA for all
retinal dystrophy genes that were listed in Retnet as of July 2010.
A recent update in January 2014 has 66 additional genes found to
have mutations causing retinal dystrophy that were not included in
the reagent used in this study. The flexibility of our approach
means that these genes can be incorporated into subsequent
versions of the targeted reagent. A methodological drawback of the
targeted hybridisation approach is that regions containing repeat
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sequences cannot be adequately covered due to binding of the
target DNA to multiple sites of repetitive sequence. In the current
reagent, 9 exons including the RPGR ORF15 could not be
covered because of repeat sequence, suggesting that these exons
will have to be sequenced using alternative methods. In terms of
data analysis, we observed a number of sequencing artefacts that
may be due to low coverage, low sequence quality or the pooling
of DNA samples but the most likely source was due to variant
calling. In order to reduce the number of false negative results the
stringency of variant calling algorithm was relaxed. This encom-
passing approach to capture all possible variants inevitably meant
that there were also a number of false positives in the annotated
variant lists.
The use of next generation sequencing for retinal disease
diagnosis has been previously described (see Table 5). Researchers
have used different target enrichment methods such as solid phase
capture arrays [9,12,14] or PCR amplicons based approaches
[8,11] as opposed to liquid phase capture [10,13] and have run the
libraries on different machines such as the Roche 454 [8,12,14] or
the ABI SOLiD [13] rather than the Illumina Genome Analyser
[8–11]. Success in identifying the pathogenic mutation has, to date
varied from 18% (3 out of 17 cases studied) [11] to 60% (3 out of 5
cases studied) [9] and there does not appear to be any correlation
between successfully identifying the pathogenic mutation and the
library preparation method or machine used for the study. The
approach described in this paper gave a 60% (12 out of 20 cases
studied) success rate, which is higher than the majority of previous
studies. One possible reason for this may be that we focussed on
studying families with multiple affected members rather than
single cases with no family history. This allowed us to assess the
pathogenicity of candidate disease causing variants by following
the transmission of the mutation with the disease phenotype. It is
interesting to note when studying isolated cases that several
examples of de novo mutations as the cause of disease have been
demonstrated [12,14]. Another possible reason for the increased
detection rate in this study is the high number of consanguineous
cases in the local Yorkshire population, which allows filtering on
the basis of homozygosity.
Patient feedback has highlighted the need for, and perceived
value of, a definitive diagnosis based on genetic testing, and has
shown that patients are motivated by a variety of factors to seek
genetic testing [32]. Individuals may see many different eye
specialists before a definitive diagnosis is made, whereas genetic
testing can rapidly provide an accurate diagnosis. Furthermore, a
genetic diagnosis can confirm the way in which the condition is
inherited, giving clearer estimates of risk for patients and their
relatives thus informing family planning decisions. Genetic testing
can also facilitate pre-implantation diagnosis or prenatal testing as
well as carrier testing in those who wish to know. In some cases
such information may lead to improvements in therapy or direct
patients towards trials for new potential therapies. It can also
provide patients with an accurate guide to future function. Using
this information, individuals can make informed decisions
regarding education, employment and lifestyle.
To conclude, we report here that tagging DNA and pooling
samples prior to hybridisation capture and next generation
sequencing is a viable high throughput method for the genetic
diagnosis of retinal dystrophies. This approach leaves a residual
cohort of patients and families with retinal dystrophy that could
not be resolved using the methods described. Their mutations may
be in the known genes within regions that were not targeted such
as the regulatory or intronic regions or one of the 9 exons of
repetitive sequence. Alternatively, the mutation may be a cryptic
splice site created by one of the synonymous variants that were
removed during filtering. On the other hand, the mutation may be
in one of the 66 additional genes that have been added to RetNet
Table 5. Comparison of the methodological approaches in recent publications that have used high throughput next generation
sequencing for retinal disease diagnosis.
Authors
[Reference]
Detecting
phenotypes Library preparation NGS instrument
Number of
independent
samples tested
Pathogenic
mutation
identified (%)
Gene number Method
Bowne et al [8] adRP 46 PCR amplicons 454GS FLX Titanium
(Roche) & GAIIx
(Illumina)
21 5 (24%)
Simpson et al [9] RP 45 Solid phase customised
capture array (NimbleGen)
GAIIx (Illumina) 5 3 (60%)
Coppieters et al [11] LCA 16 PCR amplicons GAIIx (Illumina) 17 3 (18%)
Neveling et al [12] RP 111 Solid phase customised
capture array (NimbleGen)
454GS FLX Titanium
(Roche)
100 36 (36%)
Audo et al [10] RD 254 Liquid phase targeted
SureSelect capture
(Agilent)
GAIIx (Illumina) 13 7 (54%)
O’Sullivan et al [13] RD 105 Liquid phase targeted
SureSelect capture
(Agilent)
SOLiD 4
(Life Technologies)
50 21 (42%)
Shanks et al [14] RP & CRD 73 Solid phase customised
capture array (NimbleGen)
454GS FLX Titanium
(Roche)
36 9 (25%)
Watson et al
[This paper]
RD 162 (Retnet,
July 2010)
Liquid phase targeted
SureSelect capture
(Agilent)
GAIIx (Illumina) 20 12 (60%)
adRP = autosomal dominant retinitis pigmentosa; CRD= cone rod dystrophy; LCA= leber congenital amaurosis;
RD= retinal dystrophies; RP = retinitis pigmentosa.
doi:10.1371/journal.pone.0104281.t005
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since the capturing reagent was manufactured, or it may be in a
new gene that has never been implicated in retinal dystrophy.
Nevertheless, this cohort serves as a powerful resource for further
gene and mutation discovery by whole exome as well as genome
sequencing.
Supporting Information
File S1 Supplementary figure and tables.
(PDF)
Acknowledgments
We would like to thank the patients and their families who participated in
this study.
Author Contributions
Conceived and designed the experiments: CMW DAP ES RC CAJ GT
CT CFI MA. Performed the experiments: CMW ME-A DAP JEM CVL.
Analyzed the data: CMW ME-A DAP IMC. Contributed reagents/
materials/analysis tools: MM. Wrote the paper: CMW CFI MA.
References
1. Bunce C, Xing W, Wormald R (2010) Causes of blind and partial sight
certifications in England and Wales: April 2007–March 2008. Eye 24: 1692–
1699.
2. Darr A, Modell B (1988) The frequency of consanguineous marriage among
British Pakistanis. J Med Genet 25: 186–190.
3. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al (2008) Effect
of gene therapy on visual function in Leber’s congenital amaurosis.
N Engl J Med 358: 2231–2239.
4. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, et al (2008)
Safety and efficacy of gene transfer for Leber’s congenital amaurosis.
N Engl J Med 358: 2240–2248.
5. Lamba DA, Gust J, Reh TA (2009) Transplantation of human embryonic stem
cell-derived photoreceptors restores some visual function in Crx-deficient mice.
Cell Stem Cell 4: 73–79.
6. Tan MH, Smith AJ, Pawlyk B, Xu X, Liu X, et al (2009) Gene therapy for
retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1:
effective rescue of mouse models of partial and complete Aipl1 deficiency using
AAV2/2 and AAV2/8 vectors. Hum Mol Genet 18: 2099–2114.
7. Han Z, Conley SM, Makkia RS, Cooper MJ, Naash MI (2012) DNA
nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice.
J Clin Invest 122: 3221–3226.
8. Bowne SJ, Sullivan LS, Koboldt DC, Ding L, Fulton R, et al (2011)
Identification of disease-causing mutations in autosomal dominant retinitis
pigmentosa (adRP) using next-generation DNA sequencing. Invest Ophthalmol
Vis Sci 52: 494–503.
9. Simpson DA, Clark GR, Alexander S, Silvestri G, Willoughby CE (2011)
Molecular diagnosis for heterogeneous genetic diseases with targeted high-
throughput DNA sequencing applied to retinitis pigmentosa. J Med Genet 48:
145–151.
10. Audo I, Bujakowska KM, Le´veillard T, Mohand-Said S, Lancelot ME, et al
(2012) Development and application of a next-generation-sequencing (NGS)
approach to detect known and novel gene defects underlying retinal diseases.
Orphanet J Rare Dis 7: 8.
11. Coppieters F, De Wilde B, Lefever S, De Meester E, De Rocker N, et al (2012)
Massively parallel sequencing for early molecular diagnosis in leber congenital
amaurosis. Genet Med 14: 576–585.
12. Neveling K, Collin RW, Gilissen C, van Huet RA, Visser L, et al (2012) Next-
generation genetic testing for retinitis pigmentosa. Hum Mutat 33: 963–972.
13. O’Sullivan J, Mullaney BG, Bhaskar SS, Dickerson JE, Hall G, et al (2012) A
paradigm shift in the delivery of services for diagnosis of inherited retinal disease.
J Med Genet 49: 322–326.
14. Shanks ME, Downes SM, Copley RR, Lise S, Broxholme J, et al (2013) Next-
generation sequencing (NGS) as a diagnostic tool for retinal degeneration reveals
a much higher detection rate in early-onset disease. Eur J Hum Genet 21: 274–
280.
15. Harakalova M, Mokry M, Hrdlickova B, Renkens I, Blankensteijn JD, et al
(2011) Multiplexed array-based and in-solution genomic enrichment for flexible
and cost-effective targeted next-generation sequencing. Nat Protoc 6: 1870–
1886.
16. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al (2011) A
framework for variation discovery and genotyping using next-generation DNA
sequencing data. Nat Genet 43: 491–498.
17. den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML, et al (2006)
Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber
congenital amaurosis. Am J Hum Genet 79: 556–561.
18. Lotery AJ, Jacobson SG, Fishman GA, Weleber RG, Fulton AB, et al (2001)
Mutations in the CRB1 gene cause Leber congenital amaurosis. Arch
Ophthalmol119: 415–420.
19. Singh HP, Jalali S, Hejtmancik JF, Kannabiran C (2006) Homozygous null
mutations in the ABCA4 gene in two families with autosomal recessive retinal
dystrophy. Am J Ophthalmol 141: 906–913.
20. Khan MI, Collin RW, Arimadyo K, Michael S, Azam M, et al (2010) Missense
mutations at homologous positions in the fourth and fifth laminin A G-like
domains of eyes shut homolog cause autosomal recessive retinitis pigmentosa.
Mol Vis 16: 2753–2759.
21. Sun W, Gerth C, Maeda A, Lodowski DT, Van Der Kraak L, et al (2007) Novel
RDH12 mutations associated with Leber congenital amaurosis and cone-rod
dystrophy: biochemical and clinical evaluations. Vision Res 47: 2055–2066.
22. Yang Z, Chen Y, Lillo C, Chien J, Yu Z, et al (2008) Mutant prominin 1 found
in patients with macular degeneration disrupts photoreceptor disk morphogen-
esis in mice. J Clin Invest 118: 2908–2916.
23. Michaelides M, Gaillard MC, Escher P, Tiab L, Bedell M, et al (2010) The
PROM1 mutation p.R373C causes an autosomal dominant bull’s eye
maculopathy associated with rod, rod-cone, and macular dystrophy. Invest
Ophthalmol Vis Sci 51: 4771–4780.
24. Van Ghelue M, Eriksen HL, Ponjavic V, Fagerheim T, Andreasson S, et al
(2000) Autosomal dominant cone-rod dystrophy due to a missense mutation
(R838C) in the guanylate cyclase 2D gene (GUCY2D) with preserved rod
function in one branch of the family. Ophthalmic Genet 21: 197–209.
25. Wilkie SE, Newbold RJ, Deery E, Walker CE, Stinton I, et al (2000) Functional
characterization of missense mutations at codon 838 in retinal guanylate cyclase
correlates with disease severity in patients with autosomal dominant cone-rod
dystrophy. Hum Mol Genet 9: 3065–3073.
26. Abu-Safieh L, Alrashed M, Anazi S, Alkuraya H, Khan AO, et al (2013)
Autozygome-guided exome sequencing in retinal dystrophy patients reveals
pathogenetic mutations and novel candidate disease genes. Genome Res 23:
236–247.
27. Fedick A, Jalas C, Abeliovich D, Krakinovsky Y, Ekstein J, et al (2014) Carrier
frequency of two BBS2 mutations in the Ashkenazi population. Clin Genet 85:
578–582.
28. Mackay DS, Ocaka LA, Borman AD, Sergouniotis PI, Henderson RH, et al
(2011) Screening of SPATA7 in patients with Leber congenital amaurosis and
severe childhood-onset retinal dystrophy reveals disease-causing mutations.
Invest Ophthalmol Vis Sci 52: 3032–3038.
29. Mackay DS, Dev Borman A, Moradi P, Henderson RH, Li Z, et al (2011)
RDH12 retinopathy: novel mutations and phenotypic description. Mol Vis 17:
2706–2716.
30. Cella W, Greenstein VC, Zernant-Rajang J, Smith TR, Barile G, et al (2009)
G1961E mutant allele in the Stargardt disease gene ABCA4 causes bull’s eye
maculopathy. Exp Eye Res 89: 16–24.
31. Burke TR, Fishman GA, Zernant J, Schubert C, Tsang SH, et al (2012) Retinal
phenotypes in patients homozygous for the G1961E mutation in the ABCA4
gene. Invest Ophthalmol Vis Sci 53: 4458–4467.
32. Willis TA, Potrata B, Ahmed M, Hewison J, Gale R, et al (2013) Understanding
of and attitudes to genetic testing for inherited retinal disease: a patient
perspective. Br J Ophthalmol 97: 1148–1154.
NGS for Retinal Disease Diagnosis
PLOS ONE | www.plosone.org 9 August 2014 | Volume 9 | Issue 8 | e104281
